Q-omics provides the consensus-scored ANGPT2 profile across patient tissues and cancer cell-line models. ANGPT2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ANGPT2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ANGPT2 RNA expression shows 19,529 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where ANGPT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGPT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGPT2 survival associations across molecular data types. ANGPT2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGPT2 RNA expression–survival associations across cancer types. High ANGPT2 expression shows unfavorable associations in KIRP, STAD, UVM, CESC, MESO and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ANGPT2 RNA expression.
This table summarizes ANGPT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANGPT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGPT2 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, STAD and READ. The KIRC box plot shows higher ANGPT2 RNA expression in tumor versus normal tissue (log2 FC = +3.740, t-test p < 0.001).
This table shows molecular features associated with ANGPT2 in patient tissues and cancer cell lines. In patient samples, ANGPT2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGPT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
